Seeking Alpha

The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals...

The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector